Sharon Davidov

Cooley advised Thirty Madison, a specialty healthcare company offering high-quality virtual specialized care for patients experiencing a range of conditions, on its definitive agreement to be acquired by Remedy Meds in an all-stock transaction valued in excess of $500 million.

Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.

Cooley advised Contentsquare, an all-in-one experience intelligence platform, on its definitive agreement to acquire Loris AI, a conversation intelligence platform, to give business leaders a deeper, more accurate view of the full customer journey – from click to conversation.